Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL). Among patients for whom rituximab therapy no longer provided benefit, the average duration of remission was 29.2 months after receiving the new combination vs. 14 months after bendamustine alone. The trial was stopped early based on these encouraging results.
Presented by Laurie Helen Sehn, MDCM, MPH, BC Cancer Agency, Vancouver, Canada, at ASCO 2015.
